Evotec AG has reached a Bayer milestone for advancing a program from the alliance portfolio into Phase I development for the treatment of endometriosis, triggering an undisclosed milestone payment to Evotec. The strategic alliance between the companies began October 2012 and aims to develop three clinical candidates within the five-year alliance. Both parties contribute drug targets and high-quality technology infrastructures and share the responsibility for early research and preclinical c...